Wag! Group Co.

Beth  Rescigno

Controller

Mary  Miller

Head of CRM

Mr. Garrett  Smallwood

Chairman & Chief Executive Officer

Mr. Adam  Storm

President & Chief Product Officer

Mr. Mazi  Arjomand

Chief Technology Officer

Mr. Alec  Davidian

Chief Financial Officer

Mr. Dylan  Allread

Chief Operating Officer

Mr. Nicholas  Yu

Director of Legal & General Counsel

Mr. Patrick  McCarthy

Chief Marketing Officer

Mr. David  Cane

Chief Customer Officer

Wag! Group Co. develops and supports a proprietary marketplace technology platform available as a website and mobile app that enables independent pet caregivers to connect with pet parents. Its platform allows pet parents, who require specific pet care services, such as dog walking, pet sitting and boarding, advice from licensed pet experts, home visits, training, and access to other services. The company was founded in 2015 and is based in Purchase, New York.

Considering delayed non-dilutive sources of financing, CARBIOS postpones construction of its Longlaville PET biorecycling plant for 6 to 9 months

WEST SACRAMENTO, Calif.--(BUSINESS WIRE)--Origin Materials (“Origin”) (NASDAQ: ORGN, ORGNW), a technology company with a mission to enable the world's transition to sustainable materials, today announced the production of PET caps with new features as commercial qualification continues. The latest caps were produced at our partner's facility in Germany on Origin's CapFormer System, its proprietary system for manufacturing recyclable PET closures. The caps, made with recycled PET and designed fo.

Origin Materials Continues Commercial Qualification, Announces Production of Caps with New Features

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced dosing of the first cohort of patients in the PIPE-791 Phase 1b positron emission tomography (PET) tr.

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Wag! Group Co. (NASDAQ:PET ) Q3 2024 Results Conference Call November 13, 2024 8:30 AM ET Company Participants Greg Robles - Investor Relations Garrett Smallwood - Chief Executive Officer Adam Storm - President and Chief Product Officer Alec Davidian - Chief Financial Officer Conference Call Participants Ryan Meyers - Lake Street Capital Markets Jeremy Hamblin - Craig-Hallum Matthew Koranda - ROTH Capital Operator Good morning, and welcome to the Wag! Third Quarter 2024 Earnings Conference Call.

Wag! Group Co. (PET) Q3 2024 Earnings Call Transcript

Wag! Group Co. (PET) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.06 per share a year ago.

Wag! Group Co. (PET) Reports Q3 Loss, Lags Revenue Estimates

Wag! Group Co.PET

Wag! Group Co.
PET